Reported 3 days ago
Mizuho has raised its price target for Boston Scientific Corporation (NYSE:BSX) from $130 to $140 while maintaining an Outperform rating. This adjustment follows the company's anticipated strong performance in its FARAPULSE and WATCHMAN product lines, despite a global recall of its ACURATE TAVR system. Boston Scientific, recognized as a leader in medical devices and robotics, continues to progress towards approvals for FARAPULSE in China and Japan.
Source: YAHOO